SAFETY, TOLBERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSES OF THE TRPV1 ANTAGONIST SAF312 INHEALTHY SUBJECTS.
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2014
Price : $35 *
At a glance
- Drugs SAF 312 (Primary) ; Paracetamol; Tramadol
- Indications Neurogenic bladder; Postoperative pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis
- 07 Apr 2014 New trial record
- 18 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.